Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mbIL15-BCMA CAR-T
- Development stage
- Preclinical
- Lead developer
- Obsidian Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
mbIL15-BCMA CAR-T is an investigational, autologous chimeric antigen receptor T-cell (CAR-T) therapy engineered to target B-cell maturation antigen (BCMA) and co-express a pharmacologically regulated membrane-bound interleukin-15 (mbIL15). Developed by Obsidian Therapeutics using its proprietary cytoDRiVE™ platform, the therapy features mbIL15 fused to a carbonic anhydrase 2 (CA2) drug responsive domain (DRD). This design allows for the precise, titratable control of mbIL15 expression on the cell surface via the administration of the FDA-approved small molecule ligand acetazolamide (ACZ). The regulated expression of mbIL15 is intended to promote antigen-independent CAR-T cell survival, expansion, and persistence, as well as the development of a memory stem cell phenotype, thereby enhancing anti-tumor efficacy and safety in patients with multiple myeloma.
- Other names
- mbIL15-BCMA CAR-T cellsmbIL-15-BCMA CAR-T cellsmbIL 15-BCMA CAR-T cellsregulated mbIL15-BCMA CAR-T
Beyond the preview
Go deeper on mbIL15-BCMA CAR-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mbIL15-BCMA CAR-T.